Il trapianto combinato di fegato e rene - Gastrolearning®
Upcoming SlideShare
Loading in...5
×
 

Il trapianto combinato di fegato e rene - Gastrolearning®

on

  • 512 views

Gastrolearning XVIII lezione

Gastrolearning XVIII lezione
Il trapianto combinato di fegato e rene - Prof. D. Pinna (Università di Bologna).

Statistics

Views

Total Views
512
Views on SlideShare
444
Embed Views
68

Actions

Likes
0
Downloads
6
Comments
0

3 Embeds 68

http://www.gastrolearning.it 51
http://localhost 12
http://sigeitalia.org 5

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Il trapianto combinato di fegato e rene - Gastrolearning® Il trapianto combinato di fegato e rene - Gastrolearning® Presentation Transcript

  • INDICAZIONI AL TRAPIANTOCOMBINATO DI FEGATO-RENESezione di NefrologiaSezione di NefrologiaU.O. Chirurgia generale e dei Trapianti Prof. A.D. PinnaAzienda Ospedaliera Policlinico S.Orsola-MalpighiUniversità degli Studi di Bologna
  • Liver-Kidney TransplantationBackgroundNadim M.K.et al., Am. J. Transpl. 2012
  • Liver-Kidney TransplantationBackgroundNadim M.K.et al., Am. J. Transpl. 2012
  • Liver-Kidney TransplantationBackgroundNadim M.K.et al., Am. J. Transpl. 2012
  • Liver-Kidney TransplantationBackgroundNadim M.K.et al., Am. J. Transpl. 2012
  • Liver-Kidney TransplantationBackgroundNadim M.K.et al., Am. J. Transpl. 2012
  • Liver-Kidney TransplantationBackgroundFong T.L. et al., Transplantation. 2012
  • Liver-Kidney TransplantationBackgroundMartin E.L.,et al., Liver Transpl. 2012
  • Liver-Kidney TransplantationBackgroundEason J.,et al., Am. J. Transpl. 2008
  • Liver-Kidney TransplantationBackground• Mainly the indication to combined liver-kidney transplantationis a liver disease that caused also a chronic kidney insufficiency(Serum creatinine > 2 mg/dL)• The most frequent indications are: liver cirrhosis virus or alcholrelated, policystic disease, genetics or metabolics disorders,cholestatic disease.• As a result, liver-kidney transplantation is considered a safeprocedure and the immunosuppressive regimen that should beadopted is debated• Recipient selection is critical especially within MELD-basedsystems
  • Liver-kidney transplantationAimTo report a series of liver-kidney transplantationfor adult recipients performed at a single centerand to evaluate the different results consideringindications and the impact of differentimmunosuppressive strategy
  • Liver-kidney transplantationAim
  • Liver-KidneyTransplantationMethods: study period• Retrospective study with prospectively collected data• Period: January 1997 – December 2012• 47 Liver-Kidney transplantations in adult patients• 40 (84.4%) whole liver• 7 (15.6%) split liver grafts5 Right extended – 2 Left lateral segments• Only AB0-compatible donors were used
  • • Among 57 listed patients for combined liver-kidneytransplant:4747 (82%) were effectively transplanted(82%) were effectively transplanted5 (9.1%) dead on waiting list5 (9.1%) dead on waiting list3 (5.5%) were in stand-by3 (5.5%) were in stand-by1 (1.8%) was on the waitng list1 (1.8%) was on the waitng list1 (1.8%) refused the combined liver-kidney transplant1 (1.8%) refused the combined liver-kidney transplantStudy population
  • Liver Kidney transplantationsStudy populationMELD
  • Liver-Kidney TransplantationResults: Recipient characteristics• Mean age of recipient 49.91 ± 9.87 (14-65)• Sex of recipient (M/F) 27 (57%) / 20 (43%)• Mean MELD at time of LKT 22.16 ± 7.39 (11-42)• Mean Time on waiting list (months) 8.11 ± 9.75 (0.1- 35.76)• Follow-up (years) 3.74 ± 3.01 (0.01- 9.87)
  • Liver-Kidney TransplantationResults: Recipient characteristics• Serum creatinine at listing mg/dL 4.87 ± 2.89• GFR at listing 25.38 ± 19.58• Serum creatinine at time of LKTx 4.48 ±2.49• GFR at time of LKTx 24.72 ± 18.5• Dialysis at time of LKTx 23/47
  • Liver-Kidney TransplantationResults: Outcome
  • Liver-Kidney TransplantationResults: Immunosuppressive regimen• Ciclosporine (Neoral) 5/47+• Tacrolimus (Prograf) 42/47• Induction with Alemtuzumab (Campath)(0.3 mg/kg) on day 0 and day 7 13/42• Change of immunosuppresive therapy:- Sirolimus (Rapamune) 5/47 (11%)- MMF (Cellcept) 9/47 (20%)- No change 33/47 (69%)Steroids
  • Liver Kidney transplantationResults: ComplicationsInfections 17 (37.8%)Acute cellular liver rejectionsKidney rejection3 / 47 (6%)4 / 47 (8%)De novo cancer:- Kidney cancer- Larynx cancer- Skin cancer3 /47 (6%)111
  • Liver-Kidney TransplantationResults: donor featuresAge (years) 41.9 ± 17.3 (13 – 81)Cause of deathTrauma 16 (36%)Cerebrovascular 21 (47%)Other 8 (17%)HBcore positive 8 (17%)HCV positive 1 (2%)Liver mean ischemia time (min.)Kidney mean ischemia time (min.)376 ± 83.99 (235-644)761.35 ± 168.24 (480-1380)
  • Liver-Kidney TransplantationResults: IndicationsIndication for Liver-Kidney transplantation:Liver diseasePolicistyc disease 17 (36%)CirrhosisHCVHBVAlchol11(22%)5 (11%)4 (9%)Genetic/metabolic 6 (13%)Cholestatic 2 (4%)HCC on cirrhosis 2 (4%)
  • Liver-Kidney TransplantationResults: IndicationsIndication for Liver-Kidney transplantation:Kidney diseasePolicistyc disease 16 (36%)End Stage Kidney disease 8 (18%)GN IgA 3 (6.6%)GNC 3 (6.6%)GSFS 2 (4%)Interstitial nephrites 2 (4%)Vascular disease (hypertension+diabetes) 2 (4%)Amyloidotic nephropathy 1 (2.2%)Cryoglobulinemic syndrome 1 (2.2%)Hyperoxaluria type 1 1 (2.2%)Glicogenosis 1 (2.2%)Unknown disease 5 (11%)
  • Liver Kidney TransplantationsResults: post-op. complicationsVascular complic. 3 (6%)Biliary compl. 7 (15%)Neurological compl. 3 (6%)Surgical reoperations 7 (15%)2 Liver re-TX: - HA thrombosis- Small for size syndrome2 Kidneys transplantectomy: - 2 R. V. thrombosis1 Splenectomy for platelets disorders2 Nephrectomy of native kidneyPost-operative Dialysis 7 (15%)
  • Liver-Kidney TransplantationResults: outcome100%66.7%80%60%Del Gaudio M. et al, Transpl. Proc. 2013 IN PRESS
  • Liver-Kidney TransplantationResults: outcome69.2%85.7%Del Gaudio M. et al, Transpl. Proc. 2013 IN PRESS
  • Liver-Kidney TransplantationResults: outcomeP=0.04TacrolimusThrough levelng/mLDel Gaudio M. et al, Transpl. Proc. 2013 IN PRESS
  • Liver-Kidney TransplantationResults: outcome65.6%75%Del Gaudio M. et al, Transpl. Proc. 2013 IN PRESS
  • Conclusions• Liver-kidney transplantation is a safe and effective procedure.• Even in the MELD era with cadaveric marginal donors, thetransplantation rate of listed patients is high with acceptable dropout fromthe waiting list• The standard immunosuppressive regimen based on Tacrolimus andsteroids can be ameliorated by induction therapy with Alemtuzumab(Campath).• An adjusted MELD score for this kind of recipients can be shortening thetime on waiting list